Clementia takeout to bolster Ipsen’s orphan pipeline

Ipsen Group (Euronext:IPN; Pink:IPSEY) will broaden its rare disease pipeline by acquiring Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) for $1 billion up front.

At $25 per share, the deal price is a 67% premium to Clementia's close of $14.94 on Feb. 22, before the deal was announced. Ipsen’s offer includes a $6 per share contingent value right (CVR) tied to Clementia lead compound palovarotene (R667) that is

Read the full 641 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE